ARCHIVES

FDA Expands Gleevec Indication For Children with Ph+ ALL

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Biggest NCI Budget Brings Large Headache: More Commitments, Rising Costs, Opportunities

December 8, 1989

Where’s The Money for Local Programs? Everyone Wants To Know

February 28, 1975

In Brief: Curt Appointment Now Official; Bipartisan Effort Seeks $150 Million FDA Budget Increase

April 21, 1989

NCI “Community Cancer Centers” Program in Development, House Report Reveals.

June 30, 2006

Phase II Elotuzumab Study Demonstrates 33 Months PFS

July 26, 2013

ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.

March 21, 2008